Core Laboratories (CLB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Core Laboratories (CLB) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 24. ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks S ...

Risk factors associated with technology advancement our competitors' services and products. In addition, we may not be able to adapt to evolving markets and technologies, develop or acquire new services or products, or achieve and maintain technological advantages. Our success depends, in part, on our ability to obtain patents, licenses and other intellectual property rights covering our services and products. To that end, we have obtained certain patents and intend to continue to seek patents on some of ou ...

Lawrence Bruno Right. I think it's fair to say, too, it's still real early, but with some of the focus on capturing CO2. And as that becomes maybe more available, there might be opportunities -- better opportunities to look at EOR-type projects and unconventionals, where the availability of CO2 may have been a limiting factor in that in the past. Donald Crist I think that's right. And I think it's highly operator-dependent. I don't believe I would -- it's proper to characterize that as a broad-based approac ...

Core Laboratories (CLB) reported fourth-quarter 2023 adjusted earnings of 19 cents per share, which missed the Zacks Consensus Estimate of 20 cents. The bottom line was also lower than the year-ago quarter’s reported figure of 20 cents. This could be attributed to poor performance in the Production Enhancement segment.However, this oilfield service provider’s operating revenues of $128 million were in line with the Zacks Consensus Estimate. The top line increased 0.3% from the year-ago quarter’s level of $1 ...

For the quarter ended December 2023, Core Laboratories (CLB) reported revenue of $128.21 million, up 0.5% over the same period last year. EPS came in at $0.19, compared to $0.20 in the year-ago quarter.The reported revenue represents a surprise of +0.32% over the Zacks Consensus Estimate of $127.8 million. With the consensus EPS estimate being $0.20, the EPS surprise was -5.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determ ...

Core Laboratories (CLB) came out with quarterly earnings of $0.19 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5%. A quarter ago, it was expected that this energy services company would post earnings of $0.23 per share when it actually produced earnings of $0.22, delivering a surprise of -4.35%.Over the last four quarters ...

Core Laboratories Inc. (NYSE:CLB) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Gwen Gresham - Senior Vice President, Corporate Development & Investor Relations Larry Bruno - Chairman of the Board, Chief Executive Officer and President Chris Hill - Senior Vice President, Chief Financial Officer Conference Call Participants Operator Good day and welcome to the Core Laboratories Third Quarter 2023 Earnings Conference Call. [Operator instructions] After today's presentation, ...

During the nine months ended September 30, 2023, we distributed 2,000 shares of common stock upon vesting of stock-based awards. 15 Return to Index Under the Company's Credit Facility, the SOFR plus 2.00% to SOFR plus 3.00% will be applied to outstanding borrowings. See Note 7 - Long-Term Debt, net for additional information. The Company has elected to apply the optional expedient for hedging relationships affected by reference rate reform. Accordingly, no outstanding balance on the Credit Facility with a S ...